Abstract 810P
Background
Recent studies suggested that tumor size reduction by means of pc prior to radical surgery might improve survival outcomes (SO) in CC pts. Whether pc has a beneficial effect in CC pts undergoing radical surgery in the form of total mesometrial resection (TMMR) is unclear. Because of the prevention of intraoperative tumor spillage by performing a closed colpotomy is essential to all TMMR, we hypothesized that pc would not affect SO in TMMR pts.
Methods
We performed a retrospective analysis of data which was collected in the Leipzig Mesometrial Resection trial. All pts had been treated for primary CC staged IB1 – IVA (2018-FIGO) by open abdominal hysterectomy performed as total or extended mesometrial resection (TMMR/EMMR). Recurrence-free (RFS) and overall survival (OAS) were analyzed. Cox proportional hazards regression models (Cox-R) were built to define the effect of pc. RFS and OAS within the conization group were analyzed to determine whether there is a difference between R0 (tumor removed completely) and R1 (tumor removed incompletely) conization.
Results
542 pts were included, of which 202 had received pc. After 1:1 propensity score matching including 163 pts with conization and 163 controls, pc was associated with significantly increased RFS (95.6% vs. 82.3%, HR 3.2, p<0.001) and OAS (99.2% vs. 85.6%, HR 6.4, p<0.001). In multivariable Cox-R pc was the only independent factor affecting RFS (HR 0.3, p<0.01). Analysis of the martingale residuals in a Cox regression null-model only including tumor-size revealed a continuous increase of recurrence risk with each increment in maximum tumor diameter for pts without pc, reaching a recurrence risk of 45% at a tumor size of 70 mm. In contrast, the recurrence risk for pts who had undergone pc plateaued at 12% at a tumor size of 37 mm. The sub analysis between R0 and R1 conization pts showed no difference in RFS and OAS.
Conclusions
In this study, pc was independently associated with improved survival in CC pts treated with TMMR/EMMR. Since intraoperative tumor spillage was avoided by closed colpotomy, factors other than the prevention of local tumor cell dissemination might play a role in improving survival. There is a need of further research to understand the concrete effect of pc to tumor biology.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
UKL-Universitätsklinikum Leipzig.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
779P - Assessment of the RAD51 test to determine homologous recombination deficiency (HRD) in patients (pts) with newly diagnosed advanced high-grade epithelial ovarian cancer carcinoma (HGOC)
Presenter: Carmen Garcia Duran
Session: Poster session 11
780P - Role of BRCA1 promotor methylation in homologous recombination deficiency (HRD) in high-grade ovarian cancer
Presenter: Heidelinde Fiegl
Session: Poster session 11
781P - Chemotherapy sensitivity score based on ex vivo 3D tumour testing to predict clinical response for ovarian cancer patients
Presenter: Janneke Walraven
Session: Poster session 11
782P - Correlation between chemotherapy response score (CRS) and germline BRCA1/2 (gBRCA) status in women diagnosed with FIGO stage IIIC/IV high-grade serous ovarian cancer (HGSOC)
Presenter: Daniel Netto
Session: Poster session 11
783P - The role of JARID1B in ovarian cancer
Presenter: Katharina Leitner
Session: Poster session 11
784P - HPV integration promotes HPV carcinogenesis via remodeling chromatin interactions between universal stripe factors and super-enhancer in HPV-related carcinoma
Presenter: Canhui Cao
Session: Poster session 11
785P - The predictive role of circulating exosomal PD-L1 in cervical cancer immunotherapy
Presenter: Wenjie Tang
Session: Poster session 11
786P - Antitumor activity of farletuzumab ecteribulin in a panel of endometrial cancer patient-derived xenografts with four different molecular subtypes
Presenter: Kosei Hasegawa
Session: Poster session 11
787P - A NGS panel for molecular classification of endometrial carcinoma
Presenter: Hao Wen
Session: Poster session 11
788P - Molecular profiling of p53 mutant endometrial cancer reveals distinct subgroups with opportunities for personalized therapeutic approaches
Presenter: Felix Blanc-Durand
Session: Poster session 11